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Although single-center and cross-sectional studies
have suggested a modest impact of liver donation on
donor psychological well-being, few studies have
assessed these outcomes prospectively among a
large cohort. We conducted one of the largest,
prospective, multicenter studies of psychological out-
comes in living liver donors within the Adult-to-Adult
Living Donor Liver Transplantation Cohort Study2
(A2ALL-2) consortium. In total, 271 (91%) of 297 eligi-
ble donors were interviewed at least once before
donation and at 3, 6, 12, and 24 mo after donation
using validated measures. We found that living liver
donors reported low rates of major depressive (0–
3%), alcohol abuse (2–5%), and anxiety syndromes
(2–3%) at any given assessment in their first 2 years
after donation. Between 4.7% and 9.6% of donors
reported impaired mental well-being at various time
points. We identified significant predictors for
donors’ perceptions of being better people and expe-
riencing psychological growth following donation,
including age, sex, relationship to recipient, ambiva-
lence and motivation regarding donation, and feeling
that donation would make life more worthwhile. Our
results highlight the need for close psychosocial
monitoring for those donors whose recipients died
(n=27); some of those donors experienced guilt and
concerns about responsibility. Careful screening and
targeted, data-driven follow-up hold promise for
optimizing psychological outcomes following this
procedure for potentially vulnerable donors.
Abbreviations: A2ALL2, Adult-to-Adult Living Donor
Liver Transplantation Cohort Study2; CI, confidence
interval; GEE, generalized estimating equation; HCC,
hepatocellular carcinoma; HRQOL, health-related
quality of life; LLD, living liver donor; M, months;
MCS, mental component summary; PHQ-9, Patient
Health Questionnaire 9; Pre, before donation; PRIME-
MD, Primary Care Evaluation of Mental Disorders;
PTGI-SF, Posttraumatic Growth Inventory–Short
Form; SD, standard deviation; SF-36, 36-item Short
Form Health Survey; Y, years
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Introduction
The use of living liver donation has been a critical strat-
egy in response to the shortage of deceased donor liver
grafts for patients needing this life-saving intervention;
however, living liver donors (LLDs) undergo a major
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surgical operation with no medical benefit for them-
selves. The procedure is not only physically demanding
for LLDs (1,2) but also can involve a psychological burden
(3,4). For this reason, adults chosen as LLDs are typically
healthy, both physically and emotionally (5). Given these
burdens, it is imperative to have a comprehensive under-
standing of the psychological effects of living liver dona-
tion and to ensure that long-term harm is not caused by
donation.
The longitudinal effects of donation on LLDs’ psychologi-
cal well-being have not been well characterized beyond
several single-center studies (6–8). At 6–12 mo after
donation, most LLDs report their overall psychological
well-being to be equivalent to or better than a normative
general population or a control population of healthy
adults (6), but prior studies have not systematically
assessed predonation psychological status. Despite the
overall stability in donor well-being after donation, not all
donors fare equally well (6,9–11).
From small, single-center studies, we know that LLDs
who donate to recipients with hepatocellular carcinoma
(HCC) and those who urgently donated to recipients with
acute liver failure have significantly worse mental well-
being prior to donation than normative populations (6). At
3 mo after donation, however, the mental well-being of
these LLDs is not significantly different from normative
populations (12). Some reports have suggested worse
psychological outcomes among donors whose recipients
suffered complications after transplant (3,9), whereas
other reports have not found this association (12). In a
larger cross-sectional study, past or present psychiatric
history, holding a graduate degree, and concerns about
the donor’s own well-being prior to donation were all
associated with poorer psychological outcomes com-
pared with population norms (13).
In a single-institution Japanese study, the rate of new-
onset psychiatric complications was <5% among LLDs
(14). Furthermore, in a longer term cross-sectional analy-
sis of LLDs in the Adult-to-Adult Living Donor Transplant
Cohort Study (A2ALL), most donors maintained above-
average health-related quality of life (HRQOL) up to
11 years after donation (10,15). In a recent study (16),
almost all (97%) LLDs indicated they would donate
again, regardless of complications, and similar results
were found in donors 3–9 years after donation in A2ALL
(15). Although the existing literature provides a snapshot
of the typical trajectory of psychological outcomes for
LLDs, current prospective studies of donor psychological
outcomes have not rigorously addressed potential predic-
tors of psychological outcomes (6,11,17).
Understanding the impact of liver donation surgery not
only on clinical outcomes but also on donors’ psychologi-
cal well-being is critical for several reasons. Having a
data-driven understanding of psychological outcomes is
critical for donor informed consent and helps set
expectations for postdonation recovery. An improved
understanding of psychological outcomes may include
identification of potential psychological benefits of dona-
tion. In addition, identification of donors at higher risk for
poor psychological outcomes would allow transplant cen-
ters to monitor and treat potentially vulnerable donors
during their recovery and aid in the development of tar-
geted interventions. The purpose of this study was to
evaluate trends in psychological outcomes over time and
potential predictors of these outcomes in a prospective
multicenter study of LLDs up to 2 years after donation.
Methods
Patients and study design
The A2ALL-2 consortium consists of eight U.S. transplant centers and
one transplant center in Toronto, Canada. Centers began enrolling LLDs
and their recipients between February and July 2011, and all centers
ended enrollment January 31, 2014. All centers followed the medical and
psychosocial evaluation and exclusion criteria for selecting LLDs now
included in the current U.S. national policy (18). Because our study was
observational, screening protocols were not standardized across centers.
Donors in the current prospective study of HRQOL were enrolled on or
before their scheduled donation date. Study participants were also
required to be English-speaking to participate in telephone interviews.
The study was approved by the institutional review boards and privacy
boards of the University of Michigan Data Coordinating Center and each
of the nine participating transplant centers. All donors provided written
informed consent.
Procedure
The A2ALL HRQOL study survey was implemented using computer-
assisted telephone interview methods, which ensure consistent wording
and reduce missing data by requiring a response (or reason for no
response) before advancing to subsequent questions (19–21). Interview-
ers were trained in computer-assisted telephone interview methods. Pre-
donation interviews were conducted <1 mo prior to donation, and
postdonation interviews were conducted at 3, 6, 12, and 24 mo after
donation. Participants were interviewed for 35–45 min each time and
were compensated $20 (U.S. dollars) for each completed interview. Data
collection ended July 15, 2014, after which donors who did not complete
all postdonation interviews were administratively censored (n = 29 at
1 year plus another 66 at 2 years after donation). Clinical information,
including donor hospitalizations, complications, and recipient indication for
transplantation, was abstracted from medical records.
Measures
Psychological outcomes: The major depressive, anxiety, and alcohol
abuse modules of the Primary Care Evaluation of Mental Disorders
(PRIME-MD) were assessed. Alcohol abuse was defined as any
endorsement of the following items more than once in the preceding
6 mo: drinking alcohol despite health problems, drinking alcohol during
responsibilities, missed obligations because of drinking, problems getting
along with other people because of drinking, or driving after drinking. The
PRIME-MD is a validated tool that is designed to identify clinically
significant mental health problems in primary care but that has also been
implemented successfully in other patient populations (22–24). The
modules are useful for identifying syndromes likely to meet diagnostic
criteria (25–27).
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The mental component summary (MCS) of the 36-item Short Form
Health Survey (SF-36), version 2, summarizes the mental well-being of
respondents. General population–norm-based scoring of the MCS was
used to allow comparison to the U.S. population, which is calibrated to
have a mean score of 50 and a standard deviation of 10. The SF-36 is
one of the most widely used HRQOL outcome measures in the biomedi-
cal literature (28,29).
The Posttraumatic Growth Inventory–Short Form (PTGI-SF; Cronbach’s
a = 0.93 in the present sample) is a 10-item measure used to assess
positive outcomes reported by individuals who have experienced trau-
matic events. In the present study, it was asked with reference to the
donation experience. Higher scores indicate a greater degree of per-
ceived positive change following donation. Prior research suggests that
the PTGI-SF is a useful scale for determining how well patients are able
to reconstruct or strengthen their perceptions of self, others, and the
meaning of events (30). The PTGI-SF was administered only at 1 and
2 years after donation.
The Simmons “better person” scale (Cronbach’s a = 0.78 in the pre-
sent sample) is a 10-item scale that assesses whether respondents
perceive themselves to be better people for having donated. A sample
item is, “Since the donation, I think more highly of myself.” Ratings
range from 1 (not at all true) to 10 (very true). Items are averaged,
with higher scores indicating greater perceptions of being a better
person (31).
LLDs were also asked a single question about whether they would make
the same decision to donate again. If their recipients died, LLDs were
asked a single question about whether they felt guilty about the death
and whether they felt responsible for the death (both on 1–10 scales with
1 indicating not at all guilty or responsible and 10 indicating very guilty or
responsible) (31). Guilt and responsibility were defined as scores of ≥6 on
the 10-point scale.
Potential predictors of psychological outcomes: We examined
donor demographics (age, sex, race/ethnicity, education, and marital
status), clinical characteristics (length of donation hospital stay,
postdonation rehospitalizations within the first month, and postoperative
complications within the first month), donor–recipient relationship (first-
degree relatives, spouse or partner, other biological or nonbiological
relatives, and unrelated people including friends and others), whether the
donor knew of recipient death prior to the survey time point, and
predonation survey items representing donors’ physical and mental
health and perceptions about donation.
Several predonation survey items included in the current study were
based on instruments developed to assess donor experiences during the
predonation process (31). These instruments included items that asked
about (a) other donation behavior (e.g. blood donation); (b) decision-
making items, including whether there were other possible donors for
the transplant candidate; (c) a seven-item scale that assessed ambiva-
lence about donating (Cronbach’s a = 0.57 in this sample); (d) whether
someone encouraged or discouraged the donor to donate; (e) anticipated
long-term health effects of donation; (f) feeling life would be more worth-
while if the donor donated; and (g) a two-item measure that assessed
whether donors had a history of family disapproval of their behavior in
the past (“black sheep donors”). Simmons’ (31) 11 items pertaining to
motivations to donate were averaged to summarize the motivation to
donate (Cronbach’s a = 0.77 in the present sample). The scale ranged
from 1 (weak motivation to donate) to 7 (strong motivation to donate).
Other potential predonation predictors included the Campbell global life
satisfaction item (32), which captures how donors feel about life as a
whole, the MCS and physical component summary scores from the SF-
36 (29), and the Patient Health Questionnaire 9 (PHQ-9) (33) depression
score (Cronbach’s a = 0.73 in the present sample).
Statistical analysis
Descriptive statistics were used to summarize demographic characteris-
tics of LLDs. We compared those who responded to the A2ALL HRQOL
survey with those who did not respond (did not consent or were not
interviewed) using t-tests for continuous variables and Pearson chi-square
or Fisher exact tests for categorical variables.
Among LLDs who responded to the survey, we also examined psycho-
logical characteristics over time. At each assessment time point, we cal-
culated means and standard deviations for continuous variables and
percentages for dichotomous variables. For dichotomous outcomes, we
also estimated endorsement cumulatively by calculating the percentage
who endorsed the outcome at any time after donation. PRIME-MD fac-
tors were evaluated as three separate outcomes (major depressive alco-
hol abuse, and nonpanic generalized anxiety syndromes) and as a group
of syndromes at each time point. Lasagna plots were used to illustrate
subject-specific changes over time in PRIME-MD syndromes and willing-
ness to donate again for those donors who had each outcome at any
time point (34). We hypothesized that willingness to donate again could
differ based on whether the recipient died, the length of donation hospital
stay, and whether the donor had postdonation complications. Because
only 30 donors ever reported an unwillingness to donate again during the
study period, we were not adequately powered to do multivariable mod-
eling. Instead, we used unadjusted repeated measures logistic regression
models with a generalized estimating equation (GEE) to test for these
associations.
We were interested in identifying predonation predictors of donation-
related outcomes; however, because several outcomes had low endorse-
ment, we made an a priori decision to model only binary outcomes with
endorsement >10% at a given time to help ensure reliability and general-
izability of model results. To identify predonation predictors of two con-
tinuous donation-related outcome measures—the Simmons better
person scale and PTGI-SF—GEE models with sandwich standard error
estimators were fit among donors who completed the predonation sur-
vey and at least one postdonation survey. Predictor variable selection
was guided by the method of best subsets (35), adjusted for time. Pre-
dictors were retained in models if p-values from overall tests (across all
levels for categorical variables) were <0.05 or if Bonferroni-corrected pair-
wise tests against the reference category were significant for categorical
variables.
Recipient indications for liver transplant were missing for some donors.
Consequently, to evaluate the impact of recipient diagnosis on donors’
psychological outcomes, a subgroup analysis was conducted among
donors with such information using modeling methods similar to those in
the main analysis. Recipient indications tested in this cohort included
hepatitis C virus cirrhosis, HCC and other primary hepatic malignancy,
alcohol-related cirrhosis, cryptogenic cirrhosis, primary biliary cirrhosis,
primary sclerosing cholangitis, and other liver disease or cirrhosis.
Because there could be differences in screening protocols and other fac-
tors across centers, we assessed both the magnitude of center effects
and the effect of center adjustment on other covariate coefficients (re-
flecting possible confounding). To do so, we conducted a sensitivity anal-
ysis including center indicators in final models. All statistical analyses
were performed using SAS version 9.4 (SAS Institute, Inc, Cary, NC).
Lasagna plots were generated using R version 3.2.3 (R Foundation for
Statistical Computing, Vienna, Austria).
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Results
Among 297 donors who consented to the study, 271
(91.2%) were interviewed at least once, with 245 inter-
viewed both before and after donation, eight interviewed
only before donation, and 18 interviewed only at postdo-
nation time points (Figure 1).
We compared demographic characteristics of respon-
dents (n = 271) and nonrespondents (n = 26, including
19 potential donors who did not consent and seven
actual donors who were not interviewed), and no signifi-
cant differences were found for sex, age, or race/
ethnicity (p = 0.74, p = 0.36, and p = 0.11, respectively).
Respondents were predominantly female (57%), white
271 donors with at 
least one survey 
(respondents)
278 eligible at 3 months post-donation
- 250 interviewed (90%)
- 28 not interviewed (19 refused this survey, 4 refused permanently at this 
survey, 1 missed due to communication error, 4 not approached for interview 
due to administrative error)
278 eligible at 6 months post-donation
- 241 interviewed (87%)
- 37 not interviewed (21 refused this survey, 4 refused permanently prior to this 
survey, 7 refused permanently at this survey, 1 no longer receiving care from 
A2ALL center, 4 not approached for interview due to administrative error)
278 eligible at pre-donation
- 253 interviewed (91%)
- 25 not interviewed (9 refused this survey, 11 missed due to surgery timing, 1 
missed due to communication error, 4 not approached for interview due to 
administrative error)
278 actual donors enrolled 
19 did not consent (non-respondents) *
- 16 refused to consent
- 3 not approached for consent due to 
administrative error
297 eligible actual donors
18 with only post-
donation surveys 
were analyzed 
descriptively only
245 with both pre- and at least 
one post-donation survey 
were analyzed both 
descriptively and in models
8 with only pre-
donation survey 
were analyzed 
descriptively only
249 eligible at 1 year post-donation
- 201 interviewed (81%)
- 48 not interviewed (18 refused this survey, 12 refused permanently or were 
lost to follow-up prior to this survey, 14 refused permanently at this survey, 1 
lost to follow-up, 3 not approached for interview due to administrative error)
183 eligible at 2 years post-donation
- 139 interviewed (76%)
- 44 not interviewed (15 refused this survey, 27 refused permanently or were 
lost to follow-up prior to this survey, 2 not approached for interview due to 
administrative error)
29 study ended prior to follow-up date
66 study ended prior to follow-up date
7 donors with no survey (non-respondents)
- 4 not approached for interview due to 
administrative error
- 3 refused all interviews
Figure 1: Participant flow diagram. This diagram shows the number of eligible actual donors who consented to the study, were
interviewed by the survey center, and were included in descriptive analyses and models. Donors were eligible at each time point
if they reached that time point before being administratively censored at the end of study on July 15, 2014. Note: 30 potential
donors consented to the study but did not donate and were not included in this flow chart. *Donation status for these 19 donor
candidates was unknown because they did not consent to this study. A2ALL, Adult-to-Adult Living Donor Liver Transplantation
Cohort Study.
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(80%), married (63%), and employed full time (61%)
(Table 1). Most had education beyond the high school
level (83%), and more than half donated to a first-degree
relative (53%). Only 10% (n = 27) of respondents learned
about their recipient’s death during the study follow-up
period.
Psychological characteristics
Table 2 shows the psychological characteristics by pre-
and postdonation time points. On average, donors’ res-
ponses on the better person scale and the PTGI-SF were
at about the midpoints of both scales across all time points
in which they were administered. On the better person
scale, ranging from 1 (low) to 10 (high), donors’ 3- and
6-mopostdonation scoreswere about half a point and a third
of a point higher relative to 2 years after donation, respec-
tively.Althoughdecreasing, thismagnitudeof change isunli-
kely to be clinically meaningful; nevertheless, it suggests
that feelingsofself-worthpersistover time(33).
Only 8% of donors reported they would not make the
same decision to donate again at 3 mo after donation; this
decreased to 5% at subsequent follow-up assessments.
Overall, 11% (n = 30) reported they would not donate
again at some point during the study follow-up. Although a
few of these donors indicated they would not donate again
consistently across all postdonation time points, most indi-
cated only once or twice during follow-up that they would
not donate again (Figure 2). Based on unadjusted repeated
measures regression models, donors whose recipients
died were 8.0 times more likely to report unwillingness to
donate again than donors whose recipients did not die
(95% confidence interval [CI] 2.9–22.3, p = 0.047); postdo-
nation complications and length of hospital stay were not
associated with a donor’s unwillingness to donate again
(p = 0.95 and p = 0.90, respectively).
With respect to PRIME-MD syndromes, 4–9.5% of donors
had at least one syndrome at any given time point, with lit-
tle change over time observed (Table 2). The most com-
mon syndrome was alcohol abuse (2–5%), followed by
anxiety syndrome (2–3%) and major depressive syndrome
(0–3%). Among donors with any type of syndrome at any
time point (n = 43) (Figure 3 right panel), 30 had a syn-
drome at only one time point; eight had a syndrome at two
time points; two had a syndrome at three time points; two
had a syndrome at four time points; and one had a syn-
drome at all five time points. Regarding the individual syn-
dromes, 37 had only one syndrome (yellow, red, and blue
in Figure 3) at any time, six had two syndromes (orange
and purple) during at least one time point, and no one had
all three syndromes at the same time. In addition, 26 of 43
had no syndromes before donation but developed them
during postdonation follow-up.
On average, donors’ MCS scores were similar across all
pre- and postdonation time points and were about 8 to
9.5 points higher than those of the U.S. general
population (Table 2). Before donation, 4.7% of donors
were considered impaired on the MCS (defined as 0.5
standard deviations below the U.S. normative mean);
this percentage increased to 9.6% at 3 mo after dona-
tion but then decreased back to 5% at 2 years after
donation.
Of donors reporting recipient death during the study fol-
low-up (n = 27), nine (33%) had ever felt guilty and six
(22%) had ever felt responsible for the recipient death at
some point after their recipient died.
Predictors of psychological outcomes
No binary outcomes were modeled because no out-
comes had endorsement >10% for at least one time
point to help ensure reliability of model results.
Significant predictors of the Simmons better person
scale included time since donation, relationship to recipi-
ent, sex, recipient death, and several predonation psy-
chological factors (Table 3). Scores on the better person
scale were decreasing over time until 1 year after dona-
tion. Donors donating to a first-degree relative had higher
scores compared with those donating to unrelated recipi-
ents (b = 0.84, 95% CI 0.19–1.49), on average, whereas
female donors (b = 0.70, 95% CI 1.21 to 0.18) and
donors whose recipients died (b = 1.24, 95% CI 1.89
to 0.59) had lower scores. Higher predonation ambiva-
lence, anticipation that life would be more worthwhile
after donation, higher average of donation motiva-
tions, and history of other donation behavior (actual or
intended) were all associated with higher scores on the
Simmons better person scale.
The PTGI-SF average scores were not significantly differ-
ent between 1 and 2 years after donation (Table 4).
Older donors experienced less growth (b = 1.58 per
10-year increase in age, 95% CI 2.98 to 0.17), on
average, as did those who were discouraged to donate
(b = 3.56, 95% CI 6.68 to 0.45). In contrast, donors
who anticipated before donation that their life would be
more worthwhile after donation had significantly more
growth, as measured by the PTGI-SF.
For both modeled outcomes, sensitivity analyses includ-
ing center indicators in models showed similar results for
the identified predictors. Center was significant in pre-
dicting the Simmons better person scale (overall
p = 0.03) but was not significant in predicting PTGI-SF
(p = 0.09). For the Simmons better person scale, using
the center with the largest number of donors (n = 90) as
the reference category, the differences from the other
eight centers ranged from 0.24 (p = 0.61) to 1.41
points (p < 0.001). Only the center with the 1.41-point
difference was found to be significantly different from
the reference center.
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Table 1: Demographic and donation-related characteristics of respondents (n = 271)
Characteristic Result
Female 57.2% (155)
Age at donation, mean (SD) 36.79 (10.51)
Race/ethnicity1
Non-Hispanic white 80.4% (218)
Hispanic 9.2% (25)
Native American or Alaskan Native 1.8% (5)
Asian 3.0% (8)
Black or African American 2.6% (7)
Native Hawaiian or other Pacific Islander 2.6% (7)
Other 0.4% (1)
Education at survey
High school or less 17.3% (47)
Vocational or some college 29.2% (79)
College graduate 28.8% (78)
Postgraduate 18.1% (49)
Unknown 6.6% (18)
Married or had long-term partner 63.1% (171)
Relation to transplant recipient
First-degree relative 53.1% (144)
Parent 2.2% (6)
Child 36.2% (98)
Sibling 14.8% (40)
Spouse or partner 6.3% (17)
Other biological or nonbiological relative 19.2% (52)
Unrelated4 21.4% (58)
Postdonation length of hospital stay (days), mean (SD) 5.50 (1.99)
Range 1–24
Number of postoperative complications during the first month after donation2
0 80.4% (218)
≥1 19.2% (52)
Number of hospitalizations during the first month after donation2
0 91.5% (248)
≥1 7.7% (21)
Postdonation recipient vital status from donor reported survey data (n = 263)
Donor ever aware of recipient death3 10.3% (27)
Weeks after donation that recipient death occurred (n = 27), mean (SD) 16.11 (18.22)
Predonation predictors from survey data (n = 253)
History of other donation behavior (e.g. blood donation) 71.5% (181)
There were other possible donors for the transplant candidate 41.9% (106)
Ambivalence to donate (0 = no ambivalence, 7 = highest ambivalence), mean (SD) 1.97 (1.58)
Someone encouraged the donor to donate 13.4% (34)
Someone discouraged the donor to donate 46.6% (118)
Anticipated long-term health effects of donation 51.0% (129)
Feeling life would be more worthwhile if the donor donated (1 = very unlikely, 10 = very likely),2 mean (SD) 6.80 (2.79)
History of family disapproval of donor’s behavior, % yes 28.5% (72)
Average of motivations to donate (scale of 1–7 with higher score indicating stronger motivation), mean (SD) 4.97 (0.94)
Feeling about life as a whole (1 = complete dissatisfaction, 7 = complete satisfaction), mean (SD) 6.11 (0.90)
SF-36 mental component summary, mean (SD) 58.37 (7.19)
SF-36 physical component summary, mean (SD) 56.20 (3.88)
PHQ-9 depression score (scale of 0–27), mean (SD) 1.45 (2.30)
Range 0–16
Data are shown as % (n) or mean (SD). PHQ-9, Patient Health Questionnaire-9; SD, standard deviation; SF-36, 36-item Short Form
Health Survey.
1Race/ethnicity: Native American or Alaskan Native, Asian, Black or African American, Native Hawaiian or other Pacific Islander, and
Other were collapsed into one category in the modeling and in the comparison of respondents versus nonrespondents.
2Missing <1%.
3Five participants reported that they did not know recipient vital status for at least one time point.
4Nine donors were anonymous in this unrelated group. These unrelated donors included both directed and nondirected donors.
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The subgroup analysis (n = 226) examining the effects of
recipient indications for liver transplant on donors’ psy-
chological outcomes did not reveal any recipient indica-
tion or diagnosis significantly associated with the better
person scale or the PTGI-SF, except for cryptogenic cir-
rhosis. Donors whose recipients had an indication for
transplant of cryptogenic cirrhosis had an average of 7.5
points (95% CI 0.67–14.4) more posttraumatic growth
compared with donors whose recipients’ indication for
transplant did not include cryptogenic cirrhosis.
Discussion
We conducted one of the largest multicenter prospective
studies of LLDs’ psychological well-being to date. At
2 years after donation, nearly 95% of donors interviewed
reported they would make the decision to donate again if
they could. It is useful to note, however, that up to 11%
of our sample indicated at some point during the postdo-
nation study period that they would not donate again,
and this rate is somewhat higher than reported in prior
studies of LLDs (9,36). The slight discrepancy may be
due to the fact that our participants were reporting their
experience to a survey center that was not directly asso-
ciated with the donation team.
In our cohort, we found that LLDs reported low rates of
major depressive, alcohol abuse, and anxiety syndromes
at any given time point in their first 2 years following
donation (generally <5% for any individual syndrome at
any given time point). This finding is compatible with
Table 2: Psychological outcome characteristics over time
Outcome
Predonation
(n = 253)
Postdonation,
3 mo
(n = 250)
Postdonation,
6 mo (n = 241)
Postdonation,
1 year
(n = 201)
Postdonation,
2 years
(n = 139)
Endorsement at
any postdonation
time point
(n = 263)8
Better person scale (1 = low,
10 = high)
– 5.02 (2.46) 4.71 (2.54) 4.62 (2.75) 4.57 (2.57) –
PTGI-SF (0 = low, 50 = high)1 – – – 25.23 (13.13) 24.92 (13.69) –
Would not make the same
decision to donate again2
– 8.0% (20) 4.2% (10) 5.0% (10) 5.8% (8) 11.4% (30)
Any PRIME-MD syndrome3 5.5% (14) 4.0% (10) 5.9% (14) 9.5% (19) 5.8% (8) 14.1% (37)
Major depressive
syndrome4
0.4% (1) 0.4% (1) 0.0% (0) 2.5% (5) 0.0% (0) 2.3% (6)
Alcohol abuse syndrome5 4.0% (10) 2.4% (6) 4.2% (10) 5.5% (11) 3.6% (5) 8.4% (22)
Nonpanic general anxiety
syndrome6
2.0% (5) 1.6% (4) 1.7% (4) 3.5% (7) 2.2% (3) 5.3% (14)
Donor whose recipient was
no longer alive7
– n = 13 n = 18 n = 14 n = 14 n = 27
Feel guilty about death (≥6
on scale of 1 [not at all guilty]
to 10 [very guilty])
– 7.7% (1) 33.3% (6) 21.4% (3) 0.0% (0) 33.3% (9)
Feel responsible for death
(≥6 on scale of 1 [not at all
responsible] to 10 [very
responsible])
– 0.0% (0) 22.2% (4) 21.4% (3) 7.1% (1) 22.2% (6)
General HRQOL
SF-36 MCS (U.S.
mean = 50, SD = 10,
higher is better)7
58.37 (7.19) 58.16 (9.46) 58.67 (8.32) 57.95 (10.92) 59.52 (7.53) –
SF-36 MCS impaired (<0.5
SD of the mean)7
4.7% (12) 9.6% (24) 7.9% (19) 9.5% (19) 5.0% (7) 18.6% (49)
Data are shown as % (n) or mean (SD). HRQOL, health-related quality of life; MCS, mental component summary; PHQ-9, Patient
Health Questionnaire 9; PRIME-MD, Primary Care Evaluation of Mental Disorders; PTGI-SF, Posttraumatic Growth Inventory–Short
Form; SD, standard deviation; SF-36, 36-item Short Form Health Survey.
1Missing n = 1 at 1 year.
2Missing n = 5 at 6 mo.
3Missing n = 2 at 3 mo, n = 3 at 6 mo, and n = 1 at 1 year.
4Missing n = 1 at 3 mo, n = 2 at 6 mo, and n = 1 at 1 year.
5Missing n = 3 at 6 mo.
6Missing n = 1 at 3 mo and n = 3 at 6 mo.
7Missing n = 1 at 6 mo.
8This may be underestimated, given that not all respondents responded at all time points.
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earlier A2ALL cohort research (1) and other prospective
studies (12) that have investigated rates of LLD psychi-
atric symptoms. Furthermore, our donors reported men-
tal well-being that is consistent with or better than that
of the general population and other LLD populations, on
average (6,10,11,16). That said, a minority of patients
describe impairment in this domain, even before dona-
tion (10).
Although it is generally good news that few donors expe-
rience these psychiatric syndromes or impaired mental
well-being, the fact that alcohol abuse was endorsed at
all among liver donors is worrisome. To explore a post
hoc hypothesis, we examined whether PRIME-MD–
measured alcohol abuse syndrome in donors was associ-
ated with recipient alcohol cirrhosis diagnosis—a “birds
of a feather flock together” hypothesis—but found no
association across all time points (p = 0.26). We are
aware of no prior research that has looked at drinking
behavior among LLDs. At the predonation survey, how-
ever, 4% of our sample endorsed alcohol abuse syn-
drome in the previous 6 mo. Some donors also endorsed
Figure 2: Donor-specific willingness to donate again (light gray) or not (dark gray) is shown for each survey: 3 mo, 6 mo, 1
year, and 2 years. Each row in the graph represents a donor, and white boxes indicate missing surveys. Recipient deaths that were
known to the donor are shown with black dots, with the first dot in each row representing the time point when the donor first
reported awareness of recipient death. The left side includes all donors with postdonation surveys (n = 263), and the right side shows
only donors who reported they would not donate again at one time point or more (n = 30). M, months; Y, years.
Figure 3: Donor-specific Primary Care Evaluation of Mental Disorders (PRIME-MD) syndromes by time point: predonation,
3 mo, 6 mo, 1 year, and 2 years. In the graph, each row represents a donor, and white boxes indicate missing surveys. The left side
includes all donors (n = 271), and the right side shows only donors who had any syndrome at one time point or more (n = 43). M,
months; Pre, before donation; Y, years.
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symptoms of alcohol abuse syndrome at 3- and 6-mo
postdonation surveys. Especially given the time frame
for liver regeneration in donors, it would be prudent for
LLDs to be monitored more closely for their alcohol use
both before and after donation (37).
Donors whose recipients had died were more likely to
report unwillingness to donate again compared with
donors whose recipients did not die. Furthermore, a third
of those donors whose recipients died felt guilty and
22% felt responsible at some point for the recipient’s
death. Our findings highlight that these donors may ben-
efit from additional monitoring to ensure they receive
adequate psychosocial support and treatment, if neces-
sary (10,38,39).
Our study has several strengths, including the large mul-
ticenter prospective design and the use of standardized
patient-reported outcomes to describe the sample over
time. A recent review highlighted the need for exactly
this type of prospective living donor outcomes study and
stronger evidence-based psychosocial screening criteria
(17). Consistent with prior research, we found that many
donors experienced positive psychological outcomes as a
result of their donation, including feelings of self-worth
and personal growth. Although low levels of endorse-
ment for many of the outcomes did not allow for statisti-
cal modeling, our observational findings are worth
Table 3: Predictors of Simmons better person scale (0 = low, 10 = high) from repeated measures linear regression models (n = 245)
95% CI
Regression coefficient Lower Upper p-value
Postdonation time point <.001
3 mo versus 2 years 0.58 0.30 0.86 <.001
6 mo versus 2 years 0.34 0.07 0.61 .01
1 year versus 2 years 0.12 0.14 0.37 .36
Donor–recipient relationship .054
First-degree relative versus unrelated 0.84 0.19 1.49 .012
Spouse/partner versus unrelated 0.15 1.49 1.19 .82
Other biological or nonbiological relative
versus unrelated
0.46 0.32 1.24 .25
Female versus male 0.70 1.21 0.18 .008
Recipient death (time-dependent) 1.24 1.89 0.59 <.001
Predonation predictors
Ambivalence scale (0 = no ambivalence,
7 = ambivalence)
0.24 0.07 0.40 .005
If I donate, I will feel my life is more
worthwhile (1 = very unlikely, 10 = very likely)
0.27 0.17 0.37 <.001
Average of motivations to donate (scale
of 1–7 with higher score meaning
stronger motivation)
0.61 0.31 0.91 <.001
History of other donation behavior 0.79 0.21 1.37 .008
Variables tested for inclusion but not significant: donor demographics (age at donation, race/ethnicity, education, marital status), clinical
characteristics (length of hospital stay, whether donor was rehospitalized or had complication during the first month after donation),
whether there were other possible donors for the transplant candidate, whether someone encouraged or discouraged the donor to
donate, whether donor anticipated long-term health effects of donation, “black sheep” donor, how donor felt about life as a whole,
predonation 36-item Short Form Health Survey mental and physical component summaries, and Patient Health Questionnaire 9
depression score. CI, confidence interval.
Table 4: Predictors of Posttraumatic Growth Inventory (0 = low,
50 = high) from repeated measures linear regression models
(n = 192)
Predictor
Regression
coefficient
95% CI
Lower Upper p-value
Postdonation time point
1 versus 2 years 0.22 1.57 2.02 .81
Age at donation
(per 10-year increase)
1.58 2.98 0.17 .03
If I donate, I will feel my
life is more worthwhile
(1 = very unlikely,
10 = very likely)
2.06 1.51 2.61 <.001
Anyone discouraged
to donate
3.56 6.68 0.45 .03
Variables tested for inclusion but not significant: donor demo-
graphics (sex, race/ethnicity, education, marital status), clinical
characteristics (length of hospital stay, whether donor was
rehospitalized or had complication during the first month after
donation), donor–recipient relationship, recipient death, history of
other donation behavior, whether there were other possible
donors for the transplant candidate, ambivalence to donate,
whether someone encouraged the donor to donate, whether
donor anticipated long-term health effects of donation, “black
sheep” donor, average of motivations to donate, how donor felt
about life as a whole, 36-item Short Form Health Survey mental
and physical component summaries, and Patient Health Ques-
tionnaire 9 depression score. CI, confidence interval.
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highlighting in and of themselves. Future research of
longer term psychological outcomes is warranted
because some key psychological sequelae to donation
may not become apparent until much later after the
donation experience (15).
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